VivoSeq
Metabolic & Endocrine

Hypogonadotropic Hypogonadism

27

Pipeline Programs↗

1

Active Trials↗

13

Companies Involved↗

Hypogonadotropic Hypogonadism is an emerging landscape with 27 programs across 13 companies. The most active players are Scienture, Stephanie B. Seminara, MD, Mereo BioPharma. 9 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

0/100

Mech. Concentration

38/100

Completion Rate

79/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Scienture

1 program

Phase 1S

Stephanie B. Seminara, MD

1 program

Phase 2M

Mereo BioPharma

1 program

Phase 2Takeda logo

Takeda

1 program

Phase 2E

Eastern Cooperative Oncology Group

1 program

Phase 2Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

25

clinical trials

Completed15 · 60%
Unknown status5 · 20%
Terminated4 · 16%
Recruiting1 · 4%

Clinical Trials

Trial Activity

25 trials

Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders
Recruiting·SStephanie B. Seminara, MD·Phase 2·NCT05896293·36 enrolled
Sequential Therapy for Hypogonadotropic Hypogonadism
Completed·SShanghai Jiao Tong University School of Medicine·Phase 4·NCT01403532·100 enrolled
LutrePulse Hypogonadotropic Hypogonadism
Completed·Ferring logoFerring·Phase 3·NCT01976728·39 enrolled
Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH) (MK-8962-043)
Completed·—·Phase 3·NCT03019575·17 enrolled
Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism and Effect of Testosteron Treatment
Completed·GGulhane School of Medicine·Phase 4·NCT02111434·150 enrolled
A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adult Men With Hypogonadotropic Hypogonadism (HH) (P07937)
Completed·—·Phase 3·NCT01709331·18 enrolled
Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism
Completed·MMereo BioPharma·Phase 2·NCT02730169·271 enrolled
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
Completed·RRepros Therapeutics Inc.·Phase 3·NCT01993212·120 enrolled
A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT01084265·31 enrolled
Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism
Completed·—·Phase 2·NCT04648969·18 enrolled
Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS)
Completed·MMassachusetts General Hospital·Phase 1·NCT00392756·624 enrolled
Opioid Antagonism in Hypogonadotropic Hypogonadism
Completed·—·Phase 1·NCT04975334·23 enrolled
The Effect of Testosteron Replacement Treatment on the Fibroblast Growth Factor-23, Asymmetric Dimethylarginine and Vitamin D Levels in the Congenital Hypogonadotropic Hypogonadism
Completed·GGulhane School of Medicine·Phase 4·NCT02111473·49 enrolled
A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene
Completed·RRepros Therapeutics Inc.·Phase 2·NCT02651688·50 enrolled
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
Completed·RRepros Therapeutics Inc.·Phase 3·NCT01993225·120 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)